help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jagannath, C.
Right arrow Articles by Gangadharam, P. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jagannath, C.
Right arrow Articles by Gangadharam, P. R.

Am. J. Respir. Crit. Care Med., Vol 151, No. 4, 04 1995, 1083-1086.

Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies

C Jagannath, MV Reddy, S Kailasam, JF O'Sullivan and PR Gangadharam
Department of Medicine, University of Illinois, Chicago 60612.

Clofazimine (CFM), a riminophenazine drug, is primarily used in therapy for leprosy and Mycobacterium avium infections. With an objective of identifying drugs active against Mycobacterium tuberculosis, including those with multi-drug resistance, we investigated CFM and nine of its chemical analogues. Among these, B746 and B4101 had better activity than CFM against six drug-susceptible and nine single/multiple drug- resistant M. tuberculosis strains. B746 also showed slightly better activity than CFM against intracellular M. tuberculosis in J774A.1 macrophages and was comparable to CFM in its in vivo activity against experimental tuberculosis in C57BL/6 mice. Interestingly, it caused less pigmentation in internal organs.


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
S. H. Cho, S. Warit, B. Wan, C. H. Hwang, G. F. Pauli, and S. G. Franzblau
Low-Oxygen-Recovery Assay for High-Throughput Screening of Compounds against Nonreplicating Mycobacterium tuberculosis
Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1380 - 1385.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
G. Di Perri and S. Bonora
Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?
J. Antimicrob. Chemother., September 1, 2004; 54(3): 593 - 602.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
V. M. Bulatovic, N. L. Wengenack, J. R. Uhl, L. Hall, G. D. Roberts, F. R. Cockerill III, and F. Rusnak
Oxidative Stress Increases Susceptibility of Mycobacterium tuberculosis to Isoniazid
Antimicrob. Agents Chemother., September 1, 2002; 46(9): 2765 - 2771.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
K. Peters, S. Leitzke, J. E. Diederichs, K. Borner, H. Hahn, R. H. Muller, and S. Ehlers
Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection
J. Antimicrob. Chemother., January 1, 2000; 45(1): 77 - 83.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
V. M. Reddy, J. F. O' Sullivan, and P. R. J. Gangadharam
Antimycobacterial activities of riminophenazines
J. Antimicrob. Chemother., May 1, 1999; 43(5): 615 - 623.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1995 American Thoracic Society 		  Solid Organ Transplant for the Intensivist 2008